Andere talen Lantern Pharma Inc.

Aandelen

LTRN

US51654W1018

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
6,15 ^USD	+12,02%		+11,82%	+43,69%

24/04	Transcript : Lantern Pharma Inc. - Special Call
22/04	Lantern Pharma Inc. Ontvangt goedkeuring van de regelgevende instanties om de Harmonic klinische studie voor niet-kleincellige longkanker uit te breiden naar Japan en Taiwan	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Lantern Pharma to Report First Quarter 2024 Operating and Financial Results on May 9th, 2024 at 4:30 p.m. ET	03/05
Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET	02/05
Lantern Pharma Launches Webinar Wednesdays Featuring World-Class Physician Scientists and Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development	25/04
Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development	24/04
Lantern Pharma Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan	23/04
Lantern Gets Regulatory Approval in Japan, Taiwan for Non-Small Cell Lung Cancer Trial Expansion	22/04
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan	22/04
Lantern Pharma Inc. Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smakers into Japan and Taiwan	22/04
Lantern Pharma : Corporate Overview	15/04
Lantern Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights	18/03
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284	15/03
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, Lp-284	15/03
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET	11/03
Lantern to Participate in H.C Wainwright and Co.'s 1st Annual Artificial Intelligence Based Drug Discovery and Development Virtual Conference	06/03
Lantern Pharma's A.I. Platform, RADR, Surpasses 60 Billion Data Points, Anticipates Reaching 100 Billion Data Points in 2024, paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines	05/03
Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference	05/03
Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines	04/03
Lantern Pharma Inc. Announces Series of Important Milestones Related to the Development, Size, and Advancement of RADR	04/03
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers	15/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Lantern Pharma Inc.

Aandelen

LTRN

US51654W1018

Andere talen

Filters